But we’re glad to be at this moment where we feel like we have higher visibility because the opportunity we have to get those facilities open and bring them into the company, we think is a key driver for our results, two, three years from now. So I’m not going to give you a percentage confidence level but we do have much higher visibility today, given that we’ve broken ground across many of those projects.
Andrew Mok: Great. Thanks for the color.
David Duckworth: Yes, thanks, Andrew.
Operator: Our next question will come from Gary Taylor with Cowen. Please go ahead.
Gary Taylor: Hey, good morning. I had a question. I noticed in the release and you talked about this at Investor Day, a little bit about the opportunity to add the intense outpatient programs at some of your IPF. So the question was how many of your IPFs have all three or also include partial hospitalization and the intense outpatient programs? And is there a way to sort of size the remaining revenue opportunity, either per facility or just for the total company to build out those step-down programs across all the acute hospitals.
Chris Hunter: Yes. Thanks, Gary, for the question. This is Chris. So I would say, a majority of our acute facilities, certainly, have the opportunity for step-down programs and that’s something we haven’t disclosed the exact number. Clearly, that is a focus of our clinical team led by our Chief Medical Officer, Mike Genovese, as we’re trying to continue to — we’ve added obviously that fifth growth pathway around PHP and IOP, also looking to enhance the cross-referral opportunity within the company as well. But, David, anything you would want to add on step-down programs?
David Duckworth: No. We have seen a number of new programs opened over the years. And our team has done a nice job really looking at where our patients are coming from, where we might be deflecting patients based on the level of care that’s appropriate for them and where they might be stepping down and really using that to open new programs. And it also informs our de novo strategy, just as we think about where we might have a service gap. So happy to bring on a number of new programs at our existing facilities, but it’s also really being informed and useful as we think about the de novo growth and other opportunities where the company might need to add capacity.
Gary Taylor: Could I just do a quick follow? Could you give us a sense of you have an IPF that doesn’t have those two step-down programs. You have an IPF that has kind of mature step-down programs, is the revenue differential, is it 10% higher 20% higher? Can you give us any sort of sense on what those step-down programs add to the facility profile?
David Duckworth: We would probably be ballparking it right now. But I think that 10% range is probably about right, depending on the size of their program. In some cases the facility could have a strong program that’s not only stepped down. It’s also capturing other patients in that market that may just need a different level of care. So it does vary by facility, but 10% may be the right estimate.
Gary Taylor: Thank you.
David Duckworth: Thanks, Gary.
Operator: Our next question will come from Pito Chickering with Deutsche Bank. Please, go ahead.
Kieran Ryan: Hi, there. You’ve got Kieran Ryan on here for Pito. Thanks for taking the question. I was just wondering if you could maybe break out the SMB impact in 4Q from the one-time reserve adjustment. And then I have a quick follow-up after that.
